GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rangering i aksjer
#3676
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aksjekurs
$27.23
Markedsverdi
$4.61B
Endring (1 dag)
-1.12%
Endring (1 år)
-13.12%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategori
Healthcare
Inntekter for GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Inntekter i Jun 2026 TTM: $159.96M
Ifølge GlaxoSmithKline Pharmaceuticals Limited sine nyeste økonomiske rapporter er selskapets nåværende resultat $159.96M. I 2024 hadde selskapet et resultat på $97.88M, en nedgang sammenlignet med resultatet i 2023, som var $101.78M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for GlaxoSmithKline Pharmaceuticals Limited fra 2004 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $159.96M | 8.59% |
| 2025 | $147.31M | 50.49% |
| 2024 | $97.88M | -3.82% |
| 2023 | $101.78M | -0.83% |
| 2022 | $102.63M | 65.48% |
| 2021 | $62.02M | 52.81% |
| 2020 | $40.59M | -58.72% |
| 2019 | $98.31M | 18.54% |
| 2018 | $82.93M | 5.21% |
| 2017 | $78.83M | -9.71% |
| 2016 | $87.30M | -9.89% |
| 2015 | $96.88M | -0.90% |
| 2013 | $97.77M | -35.64% |
| 2012 | $151.90M | -13.05% |
| 2011 | $174.69M | -10.43% |
| 2010 | $195.02M | 19.11% |
| 2009 | $163.74M | 13.31% |
| 2008 | $144.51M | -9.37% |
| 2007 | $159.46M | 24.82% |
| 2006 | $127.75M | 17.87% |
| 2005 | $108.38M | 10.05% |
| 2004 | $98.49M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $33.60B | 20,902.13% |
US
|
|
| $17.74B | 10,988.20% |
US
|
|
| $8.70B | 5,338.14% |
US
|
|
| $5.95B | 3,618.36% |
US
|
|
| $21.39B | 13,270.79% |
CH
|
